REVIEW OF DISEASE BURDEN OF LUNG CANCER IN CHINA'S BEIJING AND SHANGHAI

Author(s)

HU C1, Huang L2, Zhao D2, Xu L2
1Astrazeneca(China), Beijing, China, 2Astrazeneca (China), Beijing, China

OBJECTIVES: Lung cancer has now become NO.1 disease of all cancers in both incidence and mortality in China. Since lung cancer imposes great disease and economic burden on patients in China, lots of studies have investigated national status of disease burden of lung cancer. However, few studies pay attention to disease burden of lung cancer in China’s super big cities, such as Beijing &Shanghai. Our study aims to review lung cancer’s burden in Beijing and Shanghai to inform policy making. METHODS: A comprehensive literature review of disease burden of lung cancer in Beijing Shanghai was conducted. “CNKI” and “Wanfang data”, the biggest databases for Chinese journals, were searched through to Dec. 31th, 2014. RESULTS: In 2010, incidence and mortality of lung cancer in China are 46.08/10and 37.00/10CONCLUSIONS:  Lung cancer has made Chinese patients incur great loss in both DALYs and money, which is a conspicuous reminder to policy makers to pay more attention to management of the raging disease. And early prevention and screening of lung cancer should be priorities to slow increasing speed of disease burden.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PCN56

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×